AxoGen, Inc. (AXGN) CFO Sells $269,963.00 in Stock

AxoGen, Inc. (AXGN) CFO Sells $269,963.00 in Stock

AxoGen, Inc. (NASDAQ:AXGN) CFO Jamie Mark Grooms sold 10,300 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $26.21, for a total value of $269,963.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Jamie Mark Grooms also recently made the following trade(s):

  • On Thursday, February 15th, Jamie Mark Grooms sold 95,712 shares of AxoGen stock. The stock was sold at an average price of $26.84, for a total value of $2,568,910.08.
  • On Tuesday, December 12th, Jamie Mark Grooms sold 38,405 shares of AxoGen stock. The stock was sold at an average price of $26.35, for a total value of $1,011,971.75.
  • On Wednesday, December 6th, Jamie Mark Grooms sold 21,290 shares of AxoGen stock. The stock was sold at an average price of $26.22, for a total value of $558,223.80.
  • On Friday, December 8th, Jamie Mark Grooms sold 84,295 shares of AxoGen stock. The stock was sold at an average price of $26.38, for a total value of $2,223,702.10.

AxoGen, Inc. (NASDAQ AXGN) opened at $27.40 on Friday. The company has a current ratio of 3.55, a quick ratio of 2.95 and a debt-to-equity ratio of 1.93. AxoGen, Inc. has a 12 month low of $9.55 and a 12 month high of $31.70.

Several research analysts have recently commented on AXGN shares. Leerink Swann raised their price objective on AxoGen from $23.00 to $26.00 and gave the stock an “outperform” rating in a research note on Thursday, November 2nd. Wedbush reaffirmed a “buy” rating and issued a $27.00 price objective (up previously from $22.00) on shares of AxoGen in a research note on Tuesday, November 21st. Lake Street Capital raised their price objective on AxoGen from $22.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, November 21st. Jefferies Group started coverage on AxoGen in a research note on Thursday, November 30th. They issued a “buy” rating and a $35.00 price objective on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of AxoGen in a research note on Friday, January 5th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $29.33.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. raised its stake in AxoGen by 29.7% during the 4th quarter. BlackRock Inc. now owns 1,785,891 shares of the medical equipment provider’s stock valued at $50,540,000 after purchasing an additional 408,596 shares during the period. Vanguard Group Inc. raised its stake in AxoGen by 9.0% during the 2nd quarter. Vanguard Group Inc. now owns 1,223,069 shares of the medical equipment provider’s stock valued at $20,486,000 after purchasing an additional 101,245 shares during the period. Bank of New York Mellon Corp raised its stake in AxoGen by 34.6% during the 4th quarter. Bank of New York Mellon Corp now owns 849,993 shares of the medical equipment provider’s stock valued at $24,054,000 after purchasing an additional 218,430 shares during the period. Next Century Growth Investors LLC raised its stake in AxoGen by 1.7% during the 4th quarter. Next Century Growth Investors LLC now owns 667,642 shares of the medical equipment provider’s stock valued at $18,894,000 after purchasing an additional 10,876 shares during the period. Finally, Renaissance Technologies LLC raised its stake in AxoGen by 63.5% during the 4th quarter. Renaissance Technologies LLC now owns 657,800 shares of the medical equipment provider’s stock valued at $18,616,000 after purchasing an additional 255,400 shares during the period. 65.28% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This article was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.dispatchtribunal.com/2018/02/18/axogen-inc-axgn-cfo-sells-269963-00-in-stock.html.

About AxoGen

AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The company’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.

AxoGen, Inc. (NASDAQ:AXGN) CFO Jamie Mark Grooms sold 10,300 shares of the stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $26.21, for a total value of $269,963.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Jamie Mark Grooms also recently made the following trade(s):

  • On Thursday, February 15th, Jamie Mark Grooms sold 95,712 shares of AxoGen stock. The stock was sold at an average price of $26.84, for a total value of $2,568,910.08.
  • On Tuesday, December 12th, Jamie Mark Grooms sold 38,405 shares of AxoGen stock. The stock was sold at an average price of $26.35, for a total value of $1,011,971.75.
  • On Wednesday, December 6th, Jamie Mark Grooms sold 21,290 shares of AxoGen stock. The stock was sold at an average price of $26.22, for a total value of $558,223.80.
  • On Friday, December 8th, Jamie Mark Grooms sold 84,295 shares of AxoGen stock. The stock was sold at an average price of $26.38, for a total value of $2,223,702.10.

Shares of AxoGen, Inc. (NASDAQ:AXGN) opened at $27.40 on Friday. AxoGen, Inc. has a 12 month low of $9.55 and a 12 month high of $31.70. The company has a debt-to-equity ratio of 1.93, a quick ratio of 2.95 and a current ratio of 3.55.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AXGN. Bank of New York Mellon Corp grew its stake in shares of AxoGen by 293.9% in the third quarter. Bank of New York Mellon Corp now owns 631,563 shares of the medical equipment provider’s stock worth $12,222,000 after acquiring an additional 471,209 shares during the last quarter. BlackRock Inc. grew its stake in shares of AxoGen by 29.7% in the fourth quarter. BlackRock Inc. now owns 1,785,891 shares of the medical equipment provider’s stock worth $50,540,000 after acquiring an additional 408,596 shares during the last quarter. Wells Fargo & Company MN grew its stake in shares of AxoGen by 1,148.4% in the fourth quarter. Wells Fargo & Company MN now owns 432,516 shares of the medical equipment provider’s stock worth $12,240,000 after acquiring an additional 397,870 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of AxoGen by 63.5% in the fourth quarter. Renaissance Technologies LLC now owns 657,800 shares of the medical equipment provider’s stock worth $18,616,000 after acquiring an additional 255,400 shares during the last quarter. Finally, William Blair Investment Management LLC purchased a new stake in shares of AxoGen in the fourth quarter worth $5,081,000. 65.28% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities analysts have issued reports on AXGN shares. Jefferies Group started coverage on AxoGen in a report on Thursday, November 30th. They issued a “buy” rating and a $35.00 price objective for the company. Cantor Fitzgerald set a $37.00 price objective on AxoGen and gave the stock a “buy” rating in a report on Monday, January 8th. BidaskClub downgraded AxoGen from a “strong-buy” rating to a “buy” rating in a report on Thursday, January 11th. Leerink Swann increased their price objective on AxoGen from $23.00 to $26.00 and gave the stock an “outperform” rating in a report on Thursday, November 2nd. Finally, Wedbush reiterated a “buy” rating and issued a $27.00 price objective (up previously from $22.00) on shares of AxoGen in a report on Tuesday, November 21st. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $29.33.

COPYRIGHT VIOLATION WARNING: “AxoGen, Inc. (AXGN) CFO Sells $269,963.00 in Stock” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/18/axogen-inc-axgn-cfo-sells-269963-00-in-stock.html.

AxoGen Company Profile

AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The company’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply